事实上，在生物合成王浆酸领域，福瑞达不仅技术上实现了从0到1的突破，更打通了产业化路径，推动"山东好品"走向世界。 这一切的背后，是福瑞达多年来对成分创新的不懈坚持。正如鲁商集团总经理助理、福瑞达党委书记张岱州所言："成分创新是 国货实现弯道超车的关键。我们从透明质酸走向王浆酸，不仅是对中国成分的认知重塑，更是对'中国式抗衰'科技路径的坚定探 索。" 近日，山东省科学技术厅发布最新一批"山东好成果"名单，鲁商福瑞达医药股份有限公司（以下简称"福瑞达"）联合高校专家 团队研发的"生物合成王浆酸关键技术及产业化应用"项目榜上有名。彰显了这家具有"妆药同源"鲜明特色的山东国企，在合成 生物学领域的硬核科研实力。 20年攻坚撬动"液体黄金"产业化大门 这则低调的备案信息背后，昭示着振奋人心的突破：这不仅是中国首个获批用于化妆品的合成生物王浆酸原料，还宣告了全球 范围内首次实现该成分的规模化、绿色化生产，意味着王浆酸这种珍贵的生物活性物质，不再是传统的消耗性提取，而是高 效、可持续的"生物智造"。 王浆酸，具有"液体黄金"与"长寿因子"的美誉，是仅存在于蜂王浆中的稀有成分，含量仅为1.4—2.4%。科学研究表明，其在抗 ...

何 霆 ： 我是艺妙生物CEO何霆。艺妙生物是一家专注于基因细胞药物技术的生物技术公司。目前我 们主要开发针对肿瘤的新药产品。其中，首个淋巴瘤产品即将上市；同时，我们在肠癌、肝癌等实体 瘤的晚期治疗领域也有布局。此外，我们在自身免疫疾病，如红斑狼疮方向的研发也取得进展，已有 项目进入一期临床。期望持续推动基因细胞药物技术的发展，用更好的产品为更多重大疾病患者带来 治愈的希望。 连佳 ： 我是帕母医疗董事、首席执行官连佳。帕母医疗成立于2013年，至今已走过十余年。我们专 注于肺高压及心衰治疗领域，是一家基于临床价值的创新医疗器械公司。 2023年底，公司第一款产品获得中国医疗器械注册证。该产品在全球尚未有同类产品的情况下，率 先获得上市许可，成为肺高压治疗领域的首款中国原创医疗器械。目前，这款产品已在中国和欧洲取 得注册证，并即将在美国启动大型临床试验。其他几款产品也已在国内获得绿色通道资质。我们已在 中国和欧洲开展初步的商业化推广。未来，我们计划在海外推进FDA的IDE临床试验，加速全球化进 程。 刘波 ： 我是微元合成创始人刘波。我们同样专注于生物技术，但应用领域不在医药，而是面向各类 产品的生产制造。我 ...

Core Viewpoint - Huaxi Biological Technology Co., Ltd. is expected to see significant profit growth in 2025, driven by operational efficiency improvements and strategic adjustments, despite a recent decline in stock price from a peak of 313 yuan to around 50 yuan per share [1][9]. Financial Performance - The company anticipates a net profit attributable to shareholders of 270 million to 320 million yuan for 2025, representing a year-on-year increase of 54.93% to 83.63% [3][11]. - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a growth rate of 55.68% to 102.29% [3][11]. - The low base from 2024, where the total profit was 213 million yuan and net profit was 174 million yuan, contributes to the substantial growth figures [3][11]. Business Strategy and Operations - The core driver of the expected profit growth is the steady improvement in the main business, focusing on "agile management and growth efficiency" [3][11]. - The company is optimizing its organizational structure, integrating overlapping functions, and upgrading operational models to shift from "scale expansion" to "quality growth" [4][12]. - Management expenses are expected to decrease by over 10% year-on-year, while sales expenses are projected to drop by more than 30% [4][12]. Research and Innovation - Huaxi Biological is enhancing its research capabilities in glycoscience and cell biology, focusing on cutting-edge studies related to extracellular matrix regulation and aging intervention [4][12]. - The company is leveraging AI technology to optimize business processes and improve operational efficiency across the supply chain and management [4][12]. Shareholder Activity - Recently, a long-term shareholder, Guoshou Chengda, reduced its stake by 2.00%, selling approximately 9.63 million shares for about 428 million yuan [5][13]. - Following the reduction, Guoshou Chengda's holdings decreased to 4.01%, exiting the top five shareholders [5][13]. Future Outlook - Analysts expect continued improvement in the company's operations in 2026, with stable growth in raw material business and positive trends in medical terminal business [6][13]. - The skin science innovation sector is entering a reform phase, focusing on structural adjustments [6][13].

Core Viewpoint - The recent decline of nearly 3% in the Cathay Innovation Drug ETF (517110) presents a potential opportunity for investment in Chinese raw material pharmaceutical companies, which are expected to strengthen their competitive advantages [1]. Industry Summary - China's pharmaceutical and healthcare product export value is projected to grow by 3.14% by 2025, with a slight decrease of 0.27% in the export value of Western medicine raw materials [1]. - The stability in raw material drug exports reflects the competitiveness of China's raw material pharmaceutical industry amidst global trade changes and internal price competition [1]. - The outlook for 2026 indicates continued uncertainty in raw material trade, driven by price competition and advancements in synthetic biology and new production technologies that lower unit costs [1]. - Upgrades in technology are enhancing the global competitiveness of Chinese raw material pharmaceutical companies [1]. - A trend of supply clearing is ongoing, with some product prices continuing to decline; however, the potential for significant further price drops is limited compared to historical averages [1]. - Price competition pressures are beginning to impact the profits of leading companies [1]. - The competitive advantages of Chinese raw material pharmaceutical companies are expected to strengthen by 2026, with some product prices having likely bottomed out, leading to potential price recovery due to changes in competitive dynamics and production capacity utilization [1]. Company Summary - The Cathay Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which focuses on publicly listed companies engaged in the research, production, and sales of innovative drugs in the Shanghai, Shenzhen, and Hong Kong markets [1].

Group 1 - The core viewpoint is that China's API (Active Pharmaceutical Ingredient) exports are expected to remain relatively stable in total volume by 2025, despite trade changes and price competition, reflecting the industry's competitiveness [1] - In 2026, uncertainties in API trade will persist, with further competition and cooperation between China and India [1] - New technologies, such as synthetic biology, are driving down unit costs and enhancing the global competitiveness of Chinese companies in terms of quality and service efficiency [1] Group 2 - Some API prices have already bottomed out, and the trend of supply clearing is expected to continue, potentially leading to a price rebound due to changes in the competitive landscape and capacity utilization rates [1] - China's innovative pharmaceutical sector is anticipated to see a strong start in 2026, with several significant licensing deals validating technological capabilities [1] - The clinical data in the small nucleic acid drug field continues to validate its potential, accelerating market progress and attracting more leading companies to invest, which may drive the development of the supporting industrial chain [1] Group 3 - In the GLP-1 (Glucagon-like peptide-1) sector, a new pricing system is forming domestically, with rapid growth in overseas oral formulations [1] - Oral autoimmune drugs are also showing significant value [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which focuses on new drug development driven by technological innovation, reflecting the overall trend of innovation in China's pharmaceutical industry [1]

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acids since 2003, breaking the monopoly of chemical synthesis methods [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 王女士 ...

Core Viewpoint - Huaxi Biological announced an expected net profit of 270 million to 320 million yuan for 2025, representing a year-on-year growth of 54.93% to 83.63% [1] - The growth is attributed to a systematic transformation rather than short-term scale expansion, focusing on "agile management, growth, and efficiency" [1][3] Financial Performance - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] - Management expenses are expected to decrease by over 10% year-on-year in 2025 [1] Operational Strategy - The company emphasizes professional development and optimizes its business structure and resource allocation, leading to a sales expense reduction of over 30% [2] - Cost and expense management has been refined to support profit growth [2] Innovation and Digital Transformation - Huaxi Biological focuses on scientific research as its core competitive advantage, particularly in glycoscience and cell biology [2] - The company is enhancing its industrialization capabilities in bioactive substances and regenerative materials through a synthetic biology research and development system [2] - Continuous digital transformation is improving operational efficiency across all business scenarios, including AI integration in various functions [2] Long-term Development - The 2025 performance growth reflects the company's commitment to high-quality development and core capability building [3] - The company aims to maintain its competitive advantage through technological innovation and a comprehensive industrial layout [3]

Group 1 - The core viewpoint of the article is that Huaxi Biological Technology Co., Ltd. expects significant growth in net profit for the year 2025, reflecting the initial success of its strategic shift towards "quality growth" [1] - The company anticipates a net profit attributable to shareholders of between 270 million to 320 million yuan for 2025, representing an increase of approximately 54.93% to 83.63% compared to the previous year's profit of 174 million yuan [1] - The net profit excluding non-recurring gains and losses is expected to be between 167 million to 217 million yuan, with a year-on-year growth rate of 55.68% to 102.29%, indicating a strong growth momentum [1] Group 2 - The significant increase in performance is attributed to the company's commitment to the core strategy of "agile management and growth efficiency," which promotes a transition from scale expansion to quality growth [1] - The company has optimized its organizational structure and strengthened functional collaboration, leading to a notable improvement in operational efficiency, with management expenses decreasing by over 10% year-on-year [1] - Sales expenses have also seen a reduction of over 30% year-on-year due to optimized business structure and resource allocation, which has solidified the profit foundation through strict cost control [1] Group 3 - In terms of research and technological innovation, the company is focusing on two fundamental disciplines: glycoscience and cell biology, enhancing systematic research on extracellular matrix regulation, aging intervention, and tissue regeneration [2] - The company is leveraging its synthetic biology research and development system and pilot transformation platform to improve the industrialization capabilities of bioactive substances and regenerative materials, accelerating the conversion of research results into products and solutions [2] - The company is also advancing its original technology layout and product transformation in key areas such as aging intervention, tissue regeneration, and functional materials, thereby solidifying its technological foundation for medium to long-term business development [2] Group 4 - The company plans to continuously integrate artificial intelligence technology across its entire business chain to drive long-term improvements in operational quality through technology [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经华熙生物科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润人民币27,000.00万元到32,000.00万元，与上年同期（法定披露数据）相比，将 增加9,573.26万元到14,573.26万元，同比增加54.93%到83.63%。 （2）预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润16,700.00万元到21,700.00 万元，与上年同期（法定披露数据）相比，将增加5,972.80万元到10,972.80万元，同比增加55.68%到 102.29%。 二、上年同期业绩情况和财务状况 （一）利润总额：21,339.29万元。归属于母公司所有者的净利润：17,426.74万元。归属于母公司所有者 的扣除非经常性损益的净利润：10,727.20万元。 组织层面，公司整合职能重叠部门，优化 ...